Inotiv Parent, LLC emerged from Chapter 11 bankruptcy on July 19, 2026, following court confirmation of its prepackaged plan. The reorganization involved the cancellation of all existing common shares and equity interests, with no value retained by prior shareholders. New equity was issued to creditors: Prepetition First Lien Lenders received 93% of new units, while PIK Note and Convertible Note holders received approximately 7%. The company established a $180 million senior-secured Exit Credit Agreement, consisting of a $150 million term loan and $30 million in delayed draw commitments. Additionally, 630,337 warrants were issued to creditors with a $40.20 exercise price. The board was reconstituted with five managers, including CEO Robert W. Leasure Jr., while several directors and officers resigned. Inotiv operates in the life sciences industry, providing laboratory services.

The U.S. Bankruptcy Court for the Southern District of Texas confirmed Inotiv, Inc.'s amended joint prepackaged Chapter 11 plan of reorganization on July 14, 2026. Under the plan, all 35,172,908 outstanding common shares will be canceled without any distribution to existing equity holders. The reorganized company intends to issue 5,100,000 new equity interests to holders of prepetition loans, secured notes, and convertible notes, plus warrants for an additional 630,337 new equity interests. Inotiv expects to emerge from bankruptcy as a private company. Inotiv, Inc. is a contract research organization providing nonclinical and analytical drug discovery and development services.

Inotiv, Inc. entered into a $65.5 million Superpriority Secured Debtor-In-Possession (DIP) Credit Agreement on June 5, 2026, to support its Chapter 11 bankruptcy proceedings. Additionally, Nasdaq has notified the company to delist its common shares, with trading suspension scheduled for June 11, 2026.